# LAURUSLABS (LAURUSLABS) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lauruslabs

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,974
- Change: +1.33%
- As of: 2026-09-18
- 1D return: +0.30%
- 5D return: +0.46%
- 1M return: +7.07%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Laurus Labs is trading at ₹1954.0, with a technical stance indicating a bullish trend across daily, weekly, and monthly timeframes. All observed timeframes show the price trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator, suggesting consistent upward momentum. The stock has recently formed a 'Shooting Star' pattern on the daily chart, which can sometimes signal a potential pause or reversal. Despite this, the overall trend remains strong, with the price positioned near the upper end of its recent trading range, indicated by its position in range metrics for 20, 50, and 252 periods being 0.85, 0.94, and 0.98 respectively. The stock has experienced an extreme downward price movement with high volume on September 4, 2026, returning -2% on the weekly timeframe with a volume ratio of 3.68.

Nearest support is observed at ₹1935.8, followed by ₹1907.1. Resistance is noted at ₹1976.8 and ₹1981.8. The stock's risk profile includes an annualized volatility of 34% and a maximum drawdown of -19%. The current drawdown is -1%. The Average True Range (ATR) as a percentage of the price is 2.6%, indicating the typical price fluctuation range.

Key conditions to watch include the price's ability to sustain above the ₹1935.8 support level. A break below this could signal a shift in short-term momentum. Conversely, a sustained move above the nearest resistance at ₹1976.8 could indicate a continuation of the bullish trend. The recent 'Shooting Star' pattern warrants monitoring for confirmation of any potential pullback.

- Current price on September 18, 2026: ₹1954.0.
- Bullish trend observed across daily, weekly, and monthly timeframes, with price above key moving averages and Supertrend.
- Nearest support level at ₹1935.8; nearest resistance level at ₹1976.8.
- Recent 'Shooting Star' pattern on the daily chart may indicate a potential pause.
- Annualized volatility is 34%; maximum drawdown is -19%.

- Shooting Star
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal
- Outside Bar
- Inside Bar
- Harami

### News Context

Laurus Labs' strategic capital expenditure investments appear to be yielding positive results, as indicated by a report on September 15, 2026. The company's focus on Contract Development and Manufacturing Organization (CDMO) services, along with advancements in areas like peptides, antibody-drug conjugates (ADCs), and biologics, is reportedly driving its earnings and stock performance. This development suggests that the company's long-term capex strategy is aligning with market demand in these specialized pharmaceutical sectors.

In broader market context, the Indian equity markets, including the Nifty, traded positively on September 17, 2026, despite potential caution stemming from the US Federal Reserve's indications of further rate hikes in 2026. While rate-sensitive and foreign-portfolio-investment-driven segments might remain under observation, select domestic sectors saw buying interest. Market participants were monitoring currency movements, US bond yields, and foreign fund flows for directional cues.

- Laurus Labs' capital expenditure strategy is reportedly paying off, driven by CDMO orders, according to a September 15, 2026 report.
- The company's earnings and stock surge are linked to its investments in CDMO, peptides, ADCs, and biologics.
- The Sensex and Nifty traded higher on September 17, 2026, with pharma shares snapping a five-day losing streak.
- Market sentiment on September 17, 2026, was influenced by potential US rate hikes, currency movements, US bond yields, and foreign fund flows.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge

### What Changed

As of September 18, 2026, Laurus Labs (NSE) has experienced a slight increase in its stock price, moving from ₹1948.1 to ₹1954.0. The available evidence does not indicate any new filings or news developments for the company around this observation date. The company's profile and exchange listing on NSE remain unchanged from the prior context.

- Stock price increased from ₹1948.1 to ₹1954.0 between the prior observation and September 18, 2026.
- No new filings were reported for Laurus Labs as of September 18, 2026.
- No new news developments were reported for Laurus Labs as of September 18, 2026.
- The company continues to be listed on the NSE.

### Official Filings

Laurus Labs Limited has been actively engaging with investors and analysts across several scheduled meetings in August and September 2026. These engagements, including participation in the Motilal Oswal conference, Antique Pharma Investor Day, and an ICICI Securities investor meeting, are standard practice for companies to provide updates and discuss business prospects. Notably, the company has stated that no unpublished price-sensitive information will be shared during these interactions. Separately, on August 10, 2026, Laurus Labs disclosed an Environmental, Social, and Governance (ESG) score of 63 out of 100 for fiscal year 2026, as assigned by NSE Sustainability Ratings and Analytics Limited. This score was generated using publicly available data without direct company involvement. In terms of corporate structure, a composite scheme of arrangement involving the demerger of a unit from Laurus Synthesis Private Limited into Sriam Labs Private Limited, and the amalgamation of the remaining Laurus Synthesis business with Laurus Labs, is progressing. The National Company Law Tribunal (NCLT) has ordered the serving of notice for a hearing on this scheme, with the next hearing scheduled for September 10, 2026. Additionally, on July 27, 2026, the company allotted 62,635 equity shares to employees upon the exercise of stock options, increasing its total paid-up capital to ₹1,08,06,24,436, comprising 54,03,12,218 equity shares.

- Laurus Labs participated in the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai on August 19, 2026.
- The company received an ESG Score of 63 out of 100 for FY2026 from NSE Sustainability Ratings and Analytics Limited, based on publicly available data.
- A composite scheme of arrangement involving Laurus Synthesis and Sriam Labs is under review by the NCLT, with a hearing scheduled for September 10, 2026.
- On July 27, 2026, Laurus Labs allotted 62,635 equity shares to employees, increasing its paid-up capital to ₹1,08,06,24,436.
- Laurus Labs confirmed participation in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 22 to 24, 2026.

- Laurus Labs Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Laurus Labs Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Laurus Labs Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Laurus Labs Limited has informed the Exchange about Intimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited |SUBJECT: General Updates

### Fundamentals

Laurus Labs reported revenue from operations of ₹2,026.31 crore for the first quarter of fiscal year 2027 (Q1 FY27). This represents an increase from the ₹1,811.57 crore reported in the preceding quarter (Q4 FY26) and the ₹1,778.29 crore from the prior year's fourth quarter (Q4 FY26).

Further details on profitability, margins, and earnings quality are needed to assess the impact of this revenue trajectory on the company's overall financial performance and health.

- Revenue from operations for Q1 FY27 was ₹2,026.31 crore.
- This Q1 FY27 revenue marks an increase from ₹1,811.57 crore in Q4 FY26.
- The Q1 FY27 revenue also shows an increase compared to ₹1,778.29 crore in Q4 FY26.

### Bull Case

Laurus Labs' strategic investments in capacity expansion appear to be yielding positive results, as indicated by news suggesting that these long-term capital expenditure decisions are now driving earnings and stock performance. The company's focus on Contract Development and Manufacturing Organization (CDMO) orders is a key factor in this observed improvement. Technical indicators also present a constructive picture, with multiple timeframes showing bullish trends. The daily trend shows the closing price (₹1954.0) above both the 20-day EMA (₹1897.67) and 50-day EMA (₹1787.05), with positive slopes indicating upward momentum. This bullish sentiment extends to the weekly and monthly trends, which also show the supertrend indicator in a bullish direction, suggesting sustained positive momentum across different time horizons.

- News reports indicate that Laurus Labs' past capital expenditure investments are now contributing to earnings growth, driven by Contract Development and Manufacturing Organization (CDMO) orders.
- The daily technical trend is bullish, with the closing price of ₹1954.0 trading above the 20-day EMA (₹1897.67) and 50-day EMA (₹1787.05) as of 2026-09-18.
- The weekly and monthly technical trends are also exhibiting bullish signals, with the supertrend indicator in a positive direction.
- The stock has shown significant returns over various periods, including a 1-year return of 1.12 and a year-to-date return of 0.76.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge

### Bear Case

While the company's long-term capital expenditure appears to be yielding positive results, as indicated by a news headline, a review of technical indicators reveals potential cautionary signals. The stock's current price is trading above its 20-day and 50-day simple moving averages, and the supertrend indicator is bullish across daily, weekly, and monthly timeframes. However, the monthly trend shows a very high ADX of 82.71, which can indicate a strong trend but also potential for sharp reversals. The nearest resistance levels are relatively close, with the closest at ₹1976.8, only 1.17% above the current price of ₹1954.0. Additionally, the stock has experienced a maximum drawdown of -19% historically, and its annualized volatility stands at 34%, suggesting a capacity for significant price swings.

- The monthly trend shows a high ADX of 82.71 as of 2026-09-18, which can signal strong trends but also increased volatility.
- The closest resistance level is ₹1976.8, which is 1.17% above the current trading price of ₹1954.0.
- The stock has a historical maximum drawdown of -19%.
- The annualized volatility is 34%, indicating potential for significant price fluctuations.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge

### FAQs

**What recent corporate activities indicate Laurus Labs' engagement with investors and analysts?**

Laurus Labs has scheduled several investor and analyst meetings in September 2026. These include participation in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 22-24, 2026, a group investor meeting organized by ICICI Securities in Hyderabad on September 17, 2026, and involvement in the Antique Pharma Investor Day in Hyderabad on September 7, 2026. The company has stated that no unpublished price-sensitive information will be shared during these interactions.

**What does the technical analysis suggest about Laurus Labs' stock trend as of September 18, 2026?**

Technical indicators suggest a bullish trend for Laurus Labs. On a daily timeframe, the Supertrend is bullish at 1810.03, and the Exponential Moving Average (EMA) 20 is above the EMA 50, with positive slopes. Weekly and monthly timeframes also show a bullish Supertrend at 1606.36 and 1368.58, respectively, with strong positive slopes for moving averages and high ADX values (61.11 weekly, 82.71 monthly), indicating a strong trend.

**How has Laurus Labs' stock performed over different periods leading up to September 18, 2026?**

Laurus Labs has shown varied returns across different periods. The stock has returned 0.0% for the last day, 8.0% in the last month, and 43.0% in the last three months. Over a longer horizon, it has returned 99.0% in the last six months and 112.0% in the last year. Since the start of trading, the cumulative return is 217.0%, and year-to-date return stands at 76.0%.

**What are the key support and resistance levels for Laurus Labs' stock?**

As of September 18, 2026, key technical levels for Laurus Labs include support at 1935.8 (0.93% below current price), 1907.1 (2.4% below), 1866.1 (4.5% below), and 1837.4 (5.97% below). Resistance levels are identified at 1976.8 (1.17% above current price), 1981.8 (1.42% above), 2005.5 (2.64% above), and 2046.5 (4.73% above).

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge
- Laurus Labs Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Laurus Labs Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- LAURUS LABS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,935.8
- Risk regime: Price Risk Currently Contained

### Support levels
- 1811.7
- 1769.4
- 1342.9

### Resistance levels
- 1981.8
- 1976.8
- 2005.5

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.30% |
| return_10 | +4.58% |
| return_1m | +7.72% |
| return_1y | +111.64% |
| return_20 | +7.07% |
| return_3m | +42.75% |
| return_5 | +0.46% |
| return_6m | +98.70% |
| return_since_start | 2.1738812637050273 |
| return_ytd | +75.97% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.69% |
| annualized_volatility | +33.62% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and profit rise sharply from a year ago, but quarterly performance remains uneven

Laurus Labs reported revenue from operations of ₹2,026.31 crore for the quarter ended 30 June 2026, a 29% increase from the same quarter last year. Profit after tax rose 124% to ₹362.07 crore, surpassing the previous peak. However, revenue remains 37% below the September 2025 quarter’s high, and the quarterly pattern over the past five quarters has been uneven.

## Revenue Performance

Revenue from operations for Q1 FY2026-27 was ₹2,026.31 crore, compared to ₹1,811.57 crore in Q4 FY2025-26 and ₹1,569.57 crore in Q1 FY2025-26. The sequential increase of ₹214.74 crore (11.9%) and the year-over-year increase of ₹456.74 crore (29.1%) are both substantial. The latest quarter is the second-highest in the five-quarter series, but still 37% below the peak of ₹3,223.04 crore recorded in Q2 FY2025-26.

## Profitability

Profit before tax was ₹481.36 crore, up 33% from ₹361.37 crore in the previous quarter and 115% from ₹224.22 crore a year earlier. Profit after tax reached ₹362.07 crore, compared to ₹282.09 crore in Q4 FY2025-26 and ₹161.68 crore in Q1 FY2025-26. Basic earnings per share rose to ₹6.81 from ₹5.17 sequentially and ₹3.02 year-on-year.

The effective tax rate for the quarter was 24.8% (tax expense of ₹119.37 crore on profit before tax of ₹481.36 crore), down from 28.2% in the September 2025 quarter. This lower rate helped profit after tax exceed the level of that higher-revenue quarter.

## Quarterly Performance Pattern

The five quarters of available data show a pronounced spike in Q2 FY2025-26, followed by a sharp decline and a subsequent partial recovery.

| Quarter | Revenue (₹ crore) | Profit After Tax (₹ crore) |
|---------|-------------------|----------------------------|
| Q1 FY2025-26 | 1,569.57 | 161.68 |
| Q2 FY2025-26 | 3,223.04 | 356.17 |
| Q3 FY2025-26 | 1,778.29 | 251.88 |
| Q4 FY2025-26 | 1,811.57 | 282.09 |
| Q1 FY2026-27 | 2,026.31 | 362.07 |

Revenue in Q2 FY2025-26 was more than double the other quarters, which range from ₹1,570 crore to ₹2,026 crore. Profit after tax followed a similar pattern, but the latest quarter’s figure edged past the Q2 peak despite much lower revenue, reflecting the lower tax rate and a different cost structure.

## Key Takeaway

Revenue and profit both improved sharply from a year ago, but the quarterly trajectory over the past five quarters has been highly uneven. A large spike in the September 2025 quarter was followed by a decline and a subsequent partial recovery. While revenue remains significantly below that peak, profit after tax reached a new high, aided by a lower effective tax rate. The pattern highlights considerable variability in quarterly performance.

### Ratios

## Official filings

- 2026-09-18 — Earnings Presentation: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_18092026182315_InvPresentation18092026.pdf)
- 2026-09-15 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_15092026172541_Invmeet15092026.pdf)
- 2026-09-10 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_14417_WebXMLFile_20260910_130508390.xml)
- 2026-08-31 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_14417_WebXMLFile_20260831_153641987.xml)
- 2026-08-31 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_31082026153254_Invmeet31082026.pdf)
- 2026-08-12 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_14417_WebXMLFile_20260812_182446655.xml)
- 2026-08-12 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_12082026181454_Invmeet12082026.pdf)
- 2026-08-10 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_10082026193311_ESGNSEScore10082026.pdf)
- 2026-07-30 — Generic Announcement: Laurus Labs hosted an earnings conference call on July 24, 2026, to discuss Q1 FY27 results. The company reported record quarterly revenue of INR 2,026 crores, a 29% increase year-over-year, driven by strong CDMO segment growth and its affordable medicines portfolio. EBITDA margins expanded to 31.8%. The company also announced a development and commercial agreement with Aarvik Therapeutics for two ADC molecules and is nearing final land handover from the AP government. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_30072026110532_Transcript30072026.pdf)
- 2026-07-27 — Generic Announcement: On July 27, 2026, Laurus Labs Limited allotted 62,635 equity shares to 839 employees upon exercise of stock options under various ESOP schemes. The total amount received for these shares was Rs. 2,89,60,852.50. Following this allotment, the company's total paid-up capital increased to Rs. 1,08,06,24,436, comprising 54,03,12,218 equity shares. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_27072026184615_ESOPAllotmentJuly2026.pdf)
- 2026-07-25 — Generic Announcement: The Hon'ble National Company Law Tribunal (NCLT), Amravati Special Branch, has ordered Laurus Labs Limited and its subsidiaries, Laurus Synthesis Private Limited and Sriam Labs Private Limited, to serve notice of a hearing regarding a composite scheme of arrangement. This scheme involves the demerger of Laurus Synthesis's Unit-1 into Sriam Labs and the amalgamation of the remaining Laurus Synthesis business undertakings with Laurus Labs. The next hearing date is scheduled for September 10, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_25072026170941_NCLTOrder25072026.pdf)
- 2026-07-25 — Generic Announcement: Laurus Labs Limited published its unaudited financial results for the quarter ended June 30, 2026, on July 25, 2026. The company reported total revenue from operations of Rs. 2,026.31 crore and a net profit after tax of Rs. 362.07 crore for the quarter. These results were approved by the Board of Directors on July 24, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_25072026113131_NewsAd25072026.pdf)
- 2026-07-24 — Generic Announcement: Laurus Labs Limited announced that Dr. Rajesh Koshy Chandy will retire as an Independent Director effective July 26, 2026, upon completion of his second term. The Board of Directors noted this retirement during their meeting on July 24, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_24072026145231_ChangeInDirectorate24072026.pdf)
- 2026-07-24 — Generic Announcement: Laurus Labs Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 24, 2026. The results, which include standalone and consolidated figures, were reviewed by Deloitte Haskins & Sells LLP. The company reported consolidated revenue from operations of ₹2,026.31 crore and a net profit after tax of ₹361.99 crore for the quarter. Standalone revenue from operations was ₹1,757.16 crore with a net profit after tax of ₹289.96 crore. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_24072026144812_BoardOutcome24072026.pdf)
- 2026-07-24 — Official Filing: Laurus Labs Limited announced that Rajesh Koshy Chandy, a Non-Executive Independent Director, completed his tenure on July 26, 2026. This change was an outcome of a board meeting held on July 24, 2026.
- 2026-07-24 — Generic Announcement: Laurus Labs announced its Q1 FY27 financial results, reporting revenue of ₹2,026 crore, a 29% increase year-over-year, driven by strong CDMO and Affordable Medicines segments. EBITDA reached ₹644 crore with a 31.8% margin, and net profit was ₹368 crore, up 126% year-over-year. The company also highlighted continued investment in manufacturing capacity expansion and R&D, with CAPEX at 19% of sales for the quarter. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_24072026145650_InvPresentation24072026.pdf)
- 2026-07-24 — Press Release: Laurus Labs announced its unaudited financial results for the quarter ended June 30, 2026, reporting a 29% year-over-year revenue increase to ₹2,026 crore and a 66% increase in EBITDA to ₹644 crore. The company's CDMO segment saw a 67% revenue jump, while the Affordable Medicines segment grew by 10%. Laurus Labs also reported in-licensing two Antibody Drug Conjugates (ADCs) and significant R&D investments. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_24072026145845_PressRelease24072026.pdf)
- 2026-07-24 — Generic Announcement: Laurus Labs Limited hosted its Q1 FY27 Results Conference Call on July 24, 2026. An audio recording of the call is available via a provided web link, in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_24072026230016_InvestorsCallAudio24072026.pdf)
- 2026-07-14 — Generic Announcement: Laurus Labs Limited received certificates from KFin Technologies Limited, its Registrar and Share Transfer Agent, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. These certificates cover the quarter ended June 30, 2026, and confirm that details of securities dematerialized/rematerialized have been furnished to the stock exchanges where Laurus Labs Limited shares are listed. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_14072026121000_Reg74530062026.pdf)
- 2026-07-09 — Generic Announcement: Laurus Labs Limited will host a conference call on July 24, 2026, at 5:00 PM IST to discuss its Q1 FY27 results. The call, organized by DAM Capital Advisors, will include an interactive Q&A session. The company previously reported ₹ 6,813 crore in annual revenue for FY2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_09072026174507_ConcallInt24072026.pdf)
- 2026-07-09 — Official Filing: Laurus Labs Limited will hold a board meeting on July 24, 2026, to consider its unaudited quarterly financial results for the period ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to July 27, 2026.
- 2026-07-09 — Official Filing: Laurus Labs Limited will hold a virtual conference call on July 24, 2026, at 17:00 IST to discuss its Q1 FY27 results. The call details, including dial-in numbers and a registration link, are provided. Vivek Kumar is the contact person for this event.
- 2026-07-06 — Generic Announcement: Laurus Labs Limited announced that the tenure of Mrs. Aruna Bhinge as an Independent Director concluded on July 6, 2026, upon completion of her second term. This follows a previous intimation on April 30, 2026, regarding the required details under SEBI Master Circular. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06072026200359_ArunaTermCompletion.pdf)
- 2026-07-03 — Credit Rating Update: On July 03, 2026, Laurus Labs Limited received a final credit rating letter from CARE Ratings Ltd. The company's long-term bank facilities were reaffirmed at CARE AA with a Stable outlook, and its short-term bank facilities were reaffirmed at CARE A1+. These ratings reflect sustained improvement in performance during FY26, including growth in total operating income, increased profitability margins, and strengthened debt coverage indicators. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_03072026184823_CreditRating03072026.pdf)
- 2026-07-02 — Generic Announcement: Laurus Labs Limited held its 21st Annual General Meeting on July 2, 2026, via video conference, where all nine resolutions were passed by the required majority. Key resolutions included the adoption of audited financial statements for FY 2025-26, ratification of interim dividends of Rs. 0.80 and Rs. 1.20 per share, the re-appointment of directors Krishna Chaitanya Chava and Soumya Chava, and the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. The meeting also approved remuneration for non-executive directors and cost auditors for FY 2026-27. — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_02072026211046_Proceedingsof21stAGM.pdf)

## News and market events

- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-15 — MONEYCONTROL: **Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge** — Laurus Labs, CDMO, API, Satyanarayana Chava, capex investments, peptides, ADC, biologics, earnings — [Source](https://www.moneycontrol.com/news/business/laurus-labs-years-long-capex-gamble-pays-off-as-cdmo-orders-drive-earnings-stock-surge-14030269.html)
- 2026-09-09 — MONEYCONTROL: **Trade Spotlight: How should you trade Marico, Narayana Hrudayalaya, Granules, Laurus Labs, Caplin Point, Tata Technologies, and others on September 9?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-marico-narayana-hrudayalaya-granules-laurus-labs-caplin-point-tata-technologies-and-others-on-september-9-14025670.html)
- 2026-09-09 — Mint: **Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Seven stocks to buy** — Stock market today: The Indian stock market is set to open lower amid mixed global signals, with the Nifty 50 closing below 23,700. Analysts indicate weak momentum, identifying support levels around 23,600 and resistance near 23,800. Meanwhile, oil prices rise due to tensions in the Gulf region. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-trade-guide-for-sensex-nifty-50-crude-oil-to-gold-seven-stocks-to-buy-11788914980613.html)
- 2026-09-08 — Mint: **Stock market today: Gift Nifty down | Vaishali Parekh recommends three stocks to buy today** — Vaishali Parekh's stock recommendations for today: Prabhudas Lilladher expert picks three stocks for today — Lemon Tree Hotels, HBL Engineering, and Laurus Labs — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-down-vaishali-parekh-recommends-three-stocks-to-buy-today-11788834324730.html)
- 2026-09-08 — Mint: **Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | eight stocks to buy** — Stock market today: Indian stock market indices Sensex and Nifty 50 are set for a lower open on 8 September amid mixed global cues. Nifty 50 closed below 23,800, signaling bearish momentum, while elevated crude oil prices and geopolitical tensions raise concerns over inflation and market sentiment. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-trade-guide-for-sensex-nifty-50-crude-oil-to-gold-eight-stocks-to-buy-11788828251128.html)
- 2026-09-02 — BUSINESS: **Sai Life Science surges 8% in two days; stock hits new high in weak market** — In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex. — [Source](https://www.business-standard.com/markets/news/sai-life-science-surges-8-in-two-days-stock-hits-new-high-in-weak-market-126090200295_1.html)
- 2026-08-31 — CNBC-TV18: **Here's what transpired in today's CAS that triggered a 600-point jump on the Nifty Bank** — At the end of the closing auction session, the turnover logged on the NSE website showed a figure of ₹39,717 crore, the highest since the implementation of CAS. The average daily turnover has ranged between ₹1,000 crore to ₹1,200 crore. — [Source](https://www.cnbctv18.com/market/nifty-bank-sees-sharp-upmove-in-cas-record-nse-turnover-msci-rebalancing-eternal-laurus-icici-axis-adani-share-price-19980557.htm)
- 2026-08-31 — CNBC-TV18: **Eternal shares decline ahead of MSCI rebalancing, inflows worth nearly $700 million expected** — As per Nuvama Alternative and Quantitative Research, as a result of Eternal's weightage being increased in the MSCI Standard Index, it could result in potential inflows of $674 million for 205 million shares. — [Source](https://www.cnbctv18.com/market/eternal-share-price-msci-rebalancing-today-weightage-increase-inflows-impact-2026-returns-19980121.htm)
- 2026-08-31 — BUSINESS: **Lenskart up 3% ahead of MSCI rejig; Nomura calls it a generational stock** — The changes are closely watched by investors as MSCI indices are tracked by global institutional and passive funds, potentially triggering portfolio rebalancing and changes in stock-specific flows. — [Source](https://www.business-standard.com/markets/news/lenskart-up-3-ahead-of-msci-rejig-nomura-calls-it-a-generational-stock-126083100223_1.html)
- 2026-08-28 — Mint: **Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 28 August 2026** — The Indian stock market is set to open flat, following weak global trends. Major indices Nifty 50 and Sensex ended lower, with Nifty closing below 24,100. Analyst Chandan Taparia suggests cautious trading within defined ranges and recommends buying Sona BLW, Laurus Labs, and BHEL shares. — [Source](https://www.livemint.com/market/stock-market-news/shares-to-buy-or-sell-chandan-taparia-of-motilal-oswal-recommends-three-stocks-to-buy-today-28-august-2026-11787845870509.html)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-07 — MONEYCONTROL: **Laurus Labs overtakes Dr Reddy’s in market cap: key takeaways for investors** — Laurus Labs, Dr Reddys Laboratories, opinion, MCPro — [Source](https://www.moneycontrol.com/news/opinion/laurus-labs-overtakes-dr-reddy-s-in-market-cap-key-takeaways-for-investors-13997110.html)
- 2026-07-27 — Economic Times: **Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth** — Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/laurus-labs-shares-surge-over-4-as-q1fy27-profit-jumps-126-on-strong-cdmo-growth/articleshow/132653199.cms)
- 2026-07-27 — Economic Times: **Nifty in oversold territory; pullback to 24,000 possible: Analysts** — The Nifty 50 has declined and is now near oversold levels. Analysts suggest a potential pullback towards 24,000 if support at 23,600 is maintained. Traders are advised to consider specific option strategies for the upcoming weekly expiry. Several top stock picks are recommended with defined targets and stop losses. These include Azad Engineering, Laurus Labs, RR Kabel, and Astra Microwave Products. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/nifty-in-oversold-territory-pullback-to-24000-possible-analysts/articleshow/132650336.cms)
- 2026-07-26 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Monday** — Indian equities extended losses for a fifth straight session, pressured by elevated oil prices and persistent FII outflows. Despite intraday recovery, sentiment remains weak amid rising US yields and global uncertainty. Analysts flag key technical levels for Nifty, while stock-specific action and broader market resilience remain in focus. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-monday/articleshow/132640467.cms)
- 2026-07-25 — The Hindu: **Q1 Results Today Live: AU Small Finance Bank, IDFC First Bank, Dr. Reddy's Lab, Zen Tech, SBFC Finance, Birla Corporation to announce Q1 results** — Q1 Results Today, 25th July 2026 Live Updates: Track all the latest Q1 FY27 earnings announcements, corporate developments and management commentary as companies report their June quarter results. — [Source](https://www.thehindubusinessline.com/markets/stock-markets/q1-results-today-live-updates-au-small-finance-bank-idfc-first-bank-dr-reddys-lab-zen-tech-sbfc-finance-birla-corporation-results-25-july-2026/article71265209.ece)
- 2026-07-24 — The Hindu: **Generics maker Laurus Lab’s net profit more than doubles in Q1 on strong CDMO business growth** — Laurus Labs' Q1 net profit more than doubles to ₹361.99 crore, driven by significant growth in its CDMO business. — [Source](https://www.thehindu.com/business/industry/generics-maker-laurus-labs-net-profit-more-than-doubles-in-q1-on-strong-cdmo-business-growth/article71263138.ece)
- 2026-07-24 — The Hindu: **Q1 Results Today Live: Tata Consumer con. PAT up 28.4%, ACC PAT declines 61.5%, Shriram Finance, Hindustan Zinc, SBI Life, SBI Cards, Laurus Labs Q1 profit rise, BoB, NTPC, SAIL, KFin Tech to announce Q1 results** — Q1 Results Today, July 24, 2026, Live Updates: Follow businessline for more updates — [Source](https://www.thehindubusinessline.com/markets/fy27-q1-results-today-live-updates-shriram-finance-hindustan-zinc-dalmia-bharat-tata-consumer-jindal-steel-lodha-laurus-labs-sbi-life-cg-power-ntpc-infosys-indigo-cipla-results-24-july-2026/article71257341.ece)
- 2026-07-24 — CNBC-TV18: **Q1 Results LIVE Update: Bank of Baroda Q1 profit crashes 72% to ₹1,278 crore after ₹5,680 crore exceptional loss** — Q1 Results LIVE Updates: SBI Life, Shriram Finance Tata Consumer Products, NTPC, ACC, Atul, Bank of Baroda, Apar Industries, CG Power, CreditAccess Grameen, CONCOR, DCB Bank, Dalmia Bharat, Greenply Industries, Jindal Steel, Dr Lal Pathplabs, Kfin Tech, New India Assurance, Laurus Labs, Ramkrishna Forgings, Sapphire Foods, Shakti Pumps, SBI Cards, Sterlite Tech, V-Mart, Welspun Corp, are among the companies reporting their Q1 results today. Also watch for earnings reactions from Infosys, IndiGo and others. Stay tuned for all the LIVE earnings updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-infosys-indigo-shriram-finance-ntpc-tata-consumer-sbi-life-bob-boi-dcb-bank-concor-cg-power-share-price-liveblog-19952847.htm)

## Business profile

**Strategic vision:** Research-driven pharmaceutical and biotechnology company with global operations.

### Business segments
- **Pharmaceutical Ingredients:** Global supplier of Active Pharmaceutical Ingredients (APIs) and intermediates, with a focus on anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics, emphasizing backward integration.
- **Finished Dosages:** Integrates API manufacturing with R&D for finished dosage forms, operating a state-of-the-art oral finished dosage facility in Visakhapatnam, India.
- **Advanced Biologics:** Enters the biologics and biotechnology products space through its subsidiary Laurus Bio, investing in Cell and Gene therapies for healthcare and nutritional sectors.
- **Contract Development & Manufacturing Organization (CDMO):** Provides CDMO services in India for generic and proprietary drug development and manufacturing programs for global pharmaceutical and biotech companies, with Laurus Synthesis focusing on these services.

### Competitive strengths
- Backward integration capabilities within API operations.
- Global presence with manufacturing facilities and R&D centers in India and offices internationally.
- Subsidiary ecosystem focused on specialized areas like CDMO and advanced biologics.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lauruslabs
Markdown representation: https://faxioms.com/stocks/lauruslabs?render=md